Supernus Pharmaceuticals Free Cash Flow 2012-2026 | SUPN
Supernus Pharmaceuticals free cash flow from 2012 to 2026. Free cash flow can be defined as a measure of financial performance calculated as operating cash flow minus capital expenditures.
| Supernus Pharmaceuticals Annual Free Cash Flow | |
|---|---|
| 2024 | 171.23 |
| 2023 | 110.53 |
| 2022 | 116.41 |
| 2021 | 125.08 |
| 2020 | 134.71 |
| 2019 | 141.74 |
| 2018 | 128.14 |
| 2017 | 112.61 |
| 2016 | 65.21 |
| 2015 | 32.42 |
| 2014 | -25.09 |
| 2013 | -59.60 |
| 2012 | -47.95 |
| 2011 | -36.87 |
| Supernus Pharmaceuticals Quarterly Free Cash Flow | |
|---|---|
| 2026-03-31 | |
| 2025-09-30 | 26.56 |
| 2025-06-30 | 88.35 |
| 2025-03-31 | 30.27 |
| 2024-12-31 | 171.23 |
| 2024-09-30 | 127.03 |
| 2024-06-30 | 73.71 |
| 2024-03-31 | 38.15 |
| 2023-12-31 | 110.53 |
| 2023-09-30 | 65.54 |
| 2023-06-30 | 29.82 |
| 2023-03-31 | 48.85 |
| 2022-12-31 | 116.41 |
| 2022-09-30 | 88.84 |
| 2022-06-30 | 75.15 |
| 2022-03-31 | 3.45 |
| 2021-12-31 | 125.08 |
| 2021-09-30 | 76.36 |
| 2021-06-30 | 80.51 |
| 2021-03-31 | 34.24 |
| 2020-12-31 | 134.71 |
| 2020-09-30 | 103.09 |
| 2020-06-30 | 97.80 |
| 2020-03-31 | 6.38 |
| 2019-12-31 | 141.74 |
| 2019-09-30 | 98.63 |
| 2019-06-30 | 61.44 |
| 2019-03-31 | 32.77 |
| 2018-12-31 | 128.14 |
| 2018-09-30 | 95.39 |
| 2018-06-30 | 33.13 |
| 2018-03-31 | 26.88 |
| 2017-12-31 | 112.61 |
| 2017-09-30 | 77.03 |
| 2017-06-30 | 38.45 |
| 2017-03-31 | 13.06 |
| 2016-12-31 | 65.21 |
| 2016-09-30 | 40.57 |
| 2016-06-30 | 12.73 |
| 2016-03-31 | -3.42 |
| 2015-12-31 | 32.42 |
| 2015-09-30 | 13.36 |
| 2015-06-30 | 11.94 |
| 2015-03-31 | -0.45 |
| 2014-12-31 | -25.09 |
| 2014-09-30 | -31.23 |
| 2014-06-30 | -26.43 |
| 2014-03-31 | -19.37 |
| 2013-12-31 | -59.60 |
| 2013-09-30 | -49.94 |
| 2013-06-30 | -34.02 |
| 2013-03-31 | -17.60 |
| 2012-12-31 | -47.95 |
| 2012-09-30 | -31.61 |
| 2012-06-30 | -19.92 |
| 2012-03-31 | -10.11 |
| 2011-12-31 | -36.86 |
| 2011-09-30 | -28.42 |
| 2011-06-30 | -19.24 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical - Generic Drugs | $2.918B | $0.719B |
| Supernus Pharmaceuticals Inc. is a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. It is developing several product candidates in neurology and psychiatry to address opportunities in epilepsy and attention deficit hyperactivity disorder. Supernus Pharmaceuticals Inc. is based in Rockville, Maryland. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Teva Pharmaceutical Industries (TEVA) | Israel | $35.437B | 10.97 |
| BridgeBio Pharma (BBIO) | United States | $14.460B | 0.00 |
| Dr Reddy's Laboratories (RDY) | India | $11.109B | 17.29 |
| Aspen Pharmacare (APNHY) | South Africa | $3.708B | 0.00 |
| Bausch Health Cos (BHC) | Canada | $2.086B | 1.50 |
| Taysha Gene Therapies (TSHA) | United States | $1.290B | 0.00 |
| Amphastar Pharmaceuticals (AMPH) | United States | $0.924B | 7.28 |
| Personalis (PSNL) | United States | $0.630B | 0.00 |
| Assembly Biosciences (ASMB) | United States | $0.451B | 0.00 |
| Sol-Gel Technologies (SLGL) | Israel | $0.210B | 0.00 |
| Metagenomi Therapeutics (MGX) | United States | $0.052B | 0.00 |
| Evoke Pharma (EVOK) | United States | $0.019B | 0.00 |
| Teligent (TLGT) | United States | $0.000B | 0.00 |